3 Houston innovators to know this week

Who's who

This week's innovators to know includes John Berger, Mary Beth Snodgrass, and Gene Austin. Courtesy photos

Houston is still — but most accounts — emerging as a tech and innovation hub, which could seem to mean that the startups that make up the innovation ecosystem reside in early stages of business scale.

However, this week's sampling of Houston innovators to know demonstrate the scope in scale of Houston's companies — from a CEO to a newly public company and recently hired CEO of a rapidly scaling software company to a health tech leader fresh out of the gates.

John Berger, CEO of Sunnova

Photo courtesy of Sunnova

Taking a company public brings on a slew of changes. One that might be overlooked is the change for the leader of that company. John Berger —CEO of Sunnova, a Houston-based solar energy company that went public last summer — joins the Houston Innovators Podcast to discuss the changes and where his company is headed.

Transitioning from a private company CEO to a public company CEO has been eye opening, Berger says on the podcast, joking that he now has to watch what he says. But change is ultimately something Berger says he embraces.

"I really look at myself and how I can change myself," Berger says. "I'm a different CEO today than I was 12 months ago, and hopefully I'll be a different CEO in 12 months, because the company demands it." Read more and stream the episode here.

Mary Beth Snodgrass, co-founder of Healthiby

Mary Beth Snodgrass is convinced she can help people make life-enhancing changes that affect health and financial situations because, well, science.

The co-founder of Healthiby created the platform to use financial incentives to drive positive health and wellness decisions. The Houston company is in pilot mode but has plans to expand.

"What we're really focused on this year is, in addition to our incentives, digital content and coach guidance, is making sure that participants are engaging among themselves," Snodgrass tells InnovationMap. "Science shows there are benefits to surrounding yourself with other people who share similar health goals." Read more.

Gene Austin, CEO of Quorum Software

Photo courtesy of Quorum

A new CEO is tasked with exponential growth at a Houston-based software company. Gene Austin joined Houston-based Quorum Software last year at a time of rapid M&A activity.

The energy industry software solutions provider, which is a portfolio company of California-based private equity firm Thoma Bravo LLC since 2018, has big plans to continue the exponential growth with more acquisitions that diversify their portfolio of services and a Houston office expansion later this year. According to Austin, he expects this growth spurred by M&A activity to double Quorum's revenue of $200 million in the next 3 to 5 years.

"We are always thinking about how to best serve our customers," Austin says. "We've made millions of dollars of investments in our support organization and cloud team services that are foundational to reinvigorate innovation and help our customers see how the future can unfold for them." Read more.

Healthiby's motto is "health is wealth." Getty Images

Houston health and wellness startup uses money as a motivator for lifestyle changes

health is wealth

Everything is different when money is on the line, and a Houston startup is using financial incentives as a motivator for its users to make smart, healthy lifestyle changes to enhance their wellness.

Healthiby, a cost-effective wellness program, is changing the game of health solutions by addressing chronic and pre-chronic conditions through innovative prevention and management methods, all incentivized by both short-term and long-term financial benefits.

"Healthiby incentivizes and empowers people to achieve better health outcomes in a team context," says Mary Beth Snodgrass, managing director and co-founder. "We're different from other wellness solutions because we're focused on changing habits, as well as incentivizing better health outcomes, providing both immediate and long-term rewards."

The company launched in May 2019 and is still in its pilot stage. Snodgrass and co-founder Dr. Tristan Hartzell, a surgeon based in Nebraska, have remained committed to their foundational concept for their startup, which is to empower people on their wellness journeys and spread knowledge about the financial benefits of leading a healthy lifestyle.

Mary Beth Snodgrass (pictured) founded Healthiby with Nebraska-based surgeon Dr. Tristan Hartzell. Photo courtesy of Healthiby.

Healthiby's notion that "health is wealth" relates to the idea that engaging in a healthy lifestyle will ultimately benefit individuals financially long-term, as healthcare costs can be avoided. Essentially, Healthiby qualifies health goals as preventative measures for chronic and pre-chronic diseases. Not only does Healthiby inform its users about the long-term financial benefits of healthy living, the program introduces exciting contests in which users are eligible to win financial rewards if they meet certain health-related criteria.

In time for the start of the new year and the health-related resolutions buzz, Healthiby enacts their user-friendly digital software application, social programs, expert health advice and financial incentives to serve their goal-oriented consumers with an engaging health management regiment that is sure to keep them on track throughout the year.

"What we're really focused on this year is, in addition to our incentives, digital content and coach guidance, is making sure that participants are engaging among themselves," Snodgrass tells InnovationMap. "Science shows there are benefits to surrounding yourself with other people who share similar health goals."

In what the program's founders refer to as a "wellness rewards solution," users are able to tap into the Healthiby digital platform to track their progress, participate in social wellness groups, invest in long-term financial incentives and access digestible, cutting edge wellness literature; all components of Healthiby's "journey goals," the program's building blocks to achieving a healthy lifestyle.

"Our software application manages our contests and our rewards, but we also have a very social component, in which participants are meeting online regularly with a dietician coach," Snodgrass explains. "The reason for this is because when we're talking about chronic and pre-chronic conditions, it's important for people to have a strong understanding of how these issues affect the body and what kinds of lifestyle changes are most effective at helping people better manage or reverse them."

Photo courtesy of Healthiby

For an annual minimum of $8 each month, individual consumers have the opportunity to invest in their own long-term wellness through this interactive, user-friendly health progress program.

"Healthiby is providing a really low cost solution for people to get additional social motivation, information, and incentives so that they can stick with their goals throughout the year," Snodgrass said.

Healthiby is currently available to individual consumers in Texas, but its founders have their sights set on expanding the business and sharing their solutions to companies vested in the importance of healthy living for their employees. For now, Houston's health and wellness consumers just got richer — both physically and financially — when Healthiby opened its digital doors to the city.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice team keeps CO2-to-fuel devices running 50 times longer in new study

Bubbling Up

In a new study published in the journal Science, a team of Rice University researchers shared findings on how acid bubbles can improve the stability of electrochemical devices that convert carbon dioxide into useful fuels and chemicals.

The team led by Rice associate professor Hoatian Wang addressed an issue in the performance and stability of CO2 reduction systems. The gas flow channels in the systems often clog due to salt buildup, reducing efficiency and causing the devices to fail prematurely after about 80 hours of operation.

“Salt precipitation blocks CO2 transport and floods the gas diffusion electrode, which leads to performance failure,” Wang said in a news release. “This typically happens within a few hundred hours, which is far from commercial viability.”

By using an acid-humidified CO2 technique, the team was able to extend the operational life of a CO2 reduction system more than 50-fold, demonstrating more than 4,500 hours of stable operation in a scaled-up reactor.

The Rice team made a simple swap with a significant impact. Instead of using water to humidify the CO2 gas input into the reactor, the team bubbled the gas through an acid solution such as hydrochloric, formic or acetic acid. This process made more soluble salt formations that did not crystallize or block the channels.

The process has major implications for an emerging green technology known as electrochemical CO2 reduction, or CO2RR, that transforms climate-warming CO2 into products like carbon monoxide, ethylene, or alcohols. The products can be further refined into fuels or feedstocks.

“Using the traditional method of water-humidified CO2 could lead to salt formation in the cathode gas flow channels,” Shaoyun Hao, postdoctoral research associate in chemical and biomolecular engineering at Rice and co-first author, explained in the news release. “We hypothesized — and confirmed — that acid vapor could dissolve the salt and convert the low solubility KHCO3 into salt with higher solubility, thus shifting the solubility balance just enough to avoid clogging without affecting catalyst performance.”

The Rice team believes the work can lead to more scalable CO2 electrolyzers, which is vital if the technology is to be deployed at industrial scales as part of carbon capture and utilization strategies. Since the approach itself is relatively simple, it could lead to a more cost-effective and efficient solution. It also worked well with multiple catalyst types, including zinc oxide, copper oxide and bismuth oxide, which are allo used to target different CO2RR products.

“Our method addresses a long-standing obstacle with a low-cost, easily implementable solution,” Ahmad Elgazzar, co-first author and graduate student in chemical and biomolecular engineering at Rice, added in the release. “It’s a step toward making carbon utilization technologies more commercially viable and more sustainable.”

A team led by Wang and in collaboration with researchers from the University of Houston also recently shared findings on salt precipitation buildup and CO2RR in a recent edition of the journal Nature Energy.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings